All In Biotech

Free tool

FAERS Monitor: Dupixent

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761055 or its brand name (Dupixent, Dupilumab). Reports on generic versions are filed under their own applications.

Reports

518,489

Serious

57,042

11% of reports

Hospitalization

24,493

Death reported

2,351

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pruritus65,143
  • dermatitis atopic48,270
  • product use in unapproved indication44,555
  • rash41,246
  • injection site pain40,378
  • drug ineffective32,504
  • dry skin28,839
  • eczema28,786
  • product dose omission issue25,576
  • condition aggravated21,742
  • arthralgia20,813
  • inappropriate schedule of product administration19,713
  • accidental exposure to product18,392
  • asthma17,440
  • exposure via skin contact16,495

Reports by year received

View as table
YearReports
20132
20167
20171,107
20187,626
201914,912
202020,259
202140,308
202258,512
202366,771
202488,410
2025114,890
2026105,685

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,535,670 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dermatitis atopicSignal48,270423.6410.91,744,448
exposure via skin contactSignal16,49569.267.4403,966
eczemaSignal28,78648.347.5602,365
dry skinSignal28,83910.910.8204,656
product use in unapproved indicationSignal44,5558.78.6250,983
accidental exposure to productSignal18,3928.68.5101,900
pruritusSignal65,1438.18.0341,624
asthmaSignal17,4407.27.179,448
injection site painSignal40,3786.05.9148,174
inappropriate schedule of product administrationSignal19,7134.94.854,273
rashSignal41,2464.14.190,635
product dose omission issueSignal25,5763.83.748,174
condition aggravatedSignal21,7423.03.028,172
arthralgiaSignal20,8132.12.111,386
drug ineffective32,5041.01.00

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.